Casos de lesão hepática foram registrados em Victoria, Austrália, após o uso de produtos com retatrutida, substância para obesidade e diabetes. Autoridades suspeitam de contaminantes em versões ilegais comercializadas online.
Senior doctors in Melbourne are warning the public against taking unapproved weight loss medication labelled as retatrutide, after multiple cases of severe liver damage and other illnesses were discovered. The injectable drug, not approved by any global regulator, is being sold on the black market, with one woman hospitalised in acute liver failure after just two doses.
Senior doctors in Melbourne are warning the public against using an unapproved weight loss drug labeled as retatrutide, after multiple cases of severe liver damage and other serious illnesses were reported. The injectable medication, not approved by any global drug regulator, is being sold on the black market.
Retatrutide, a new obesity drug from Eli Lilly, has shown a 30% weight loss in trials, surpassing previous drugs like Ozempic. It mimics GLP-1 and other hormones, offering benefits beyond weight loss, including anti-inflammatory effects.
Retatrutide, a new obesity drug, has shown a 30% weight loss in trials, surpassing previous drugs. Experts highlight its broader benefits beyond weight loss, including reduced inflammation and improved cardiovascular and kidney function, attributing these to its multi-organ receptor action.
A new drug called retatrutide has shown significant weight loss results in a study, with participants losing up to 28.3% of their body weight. The drug targets three hormonal pathways simultaneously, leading to greater weight loss than current medications.
Eli Lilly's new obesity drug, retatrutide, showed significant weight loss in a late-stage trial, with the highest dose leading to an average loss of 28.3% over 80 weeks. The drug targets three gut hormones and appears more effective than existing treatments, bringing Lilly closer to regulatory approval.
